Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real ‐world evidence using a nationwide database

International Journal of Rheumatic Diseases, EarlyView.

Source: APLAR Journal of Rheumatology - April 18, 2018 Category: Rheumatology Authors: Jiyoun Kim , Dongmun Ha , Inmyung Song , Haesun Park , Sang ‐Won Lee , Eui‐Kyung Lee , Ju‐Young Shin Source Type: research